Skip to main content

Table 3 Standardized incidence ratio of NADMs in PLWHA on antiretroviral therapy

From: Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development

Age/Sex group

Number of NADM

Standardized Incidence ratios (95% CI)

Actual

Expecteda

All NADMs

 20–39/Male

20

3.69

5.42 (3.31,8.38)

 20–39/Female

3

1.88

1.60 (0.33, 4.66)

 40–59/Male

80

37.58

2.13 (1.69,2.65)

 40–59/Female

11

6.92

1.59 (0.79, 2.85)

 60–79/Male

29

19.40

1.49 (1.00,2.15)

 60–79/Female

2

1.31

1.53 (0.18, 5.52)

 Total

145

70.78

2.05 (1.73, 2.41)

Lung Cancer

 20–39/Male

1

0.06

16.55 (0.42, 92.21)

 20–39/Female

0

0.03

0 (0, 118.43)

 40–59/Male

14

4.16

3.37 (1.84, 5.65)

 40–59/Female

4

0.63

6.37 (1.74, 16.31)

 60–79/Male

11

2.90

3.80 (1.90, 6.79)

 60–79/Female

0

0.24

0 (0, 15.55)

 Total

30

8.02

3.74 (2.52, 5.34)

Anal Cancer

 20–39/Male

5

0.08

64.55 (20.98, 150.66)

 20–39/Female

0

0.005

0 (0, 749.71)

 40–59/Male

21

2.50

8.39 (5.19, 12.82)

 40–59/Female

1

0.26

3.82 (0.10, 21.29)

 60–79/Male

2

0.99

2.02 (0.24, 7.30)

 60–79/Female

0

0.05

0 (0, 69.03)

 Total

29

3.89

7.46 (4.99, 10.70)

  1. aExpected number of NADMs are based on population incidence for that NADM